Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Oppenheimer increased their FY2019 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research report issued on Wednesday. Oppenheimer analyst J. Olson now expects that the company will earn $1.47 per share for the year, up from their prior forecast of $1.41. Oppenheimer currently has a “Buy” rating and a $100.00 target price on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2021 earnings at $7.71 EPS and FY2022 earnings at $8.57 EPS.
NBIX has been the topic of a number of other reports. Jefferies Group increased their price objective on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a report on Friday, January 5th. Citigroup reissued a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Needham & Company LLC reissued a “buy” rating and issued a $86.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Piper Jaffray Companies reissued a “buy” rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Finally, JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $79.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $88.79.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same quarter in the previous year, the company earned ($0.51) earnings per share.
Hedge funds have recently modified their holdings of the business. Crow Point Partners LLC purchased a new position in Neurocrine Biosciences during the fourth quarter worth approximately $145,000. American International Group Inc. purchased a new position in Neurocrine Biosciences during the fourth quarter worth approximately $161,000. M&T Bank Corp purchased a new position in Neurocrine Biosciences during the fourth quarter worth approximately $202,000. Mission Wealth Management LP purchased a new position in Neurocrine Biosciences during the fourth quarter worth approximately $204,000. Finally, The Manufacturers Life Insurance Company boosted its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares in the last quarter.
In other news, insider Dimitri E. Grigoriadis sold 71,775 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.98, for a total value of $5,597,014.50. Following the sale, the insider now owns 154,717 shares in the company, valued at $12,064,831.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. Insiders sold 337,950 shares of company stock worth $26,613,876 in the last 90 days. Company insiders own 4.80% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.